即使无法实现肉眼完全切除,最大程度肿瘤细胞减灭术仍可改善卵巢癌患者生存
该研究纳入2003至2011年接受初次肿瘤细胞减灭术的FIGO(2009)IIIC期卵巢癌患者447例,按残留病灶(RD)分层分析生存。结果显示RD0患者中位总生存最长(58个月),RD 0.1-1.0cm优于RD>1cm;实施细胞减灭标准化后RD0比例提高、30天死亡率下降、中位总生存延长。
要点
- RD0患者中位总生存58个月,RD 0.1-0.5cm为35个月,RD 0.6-1.0cm为29个月,RD>1cm为22个月。
- RD0生存显著优于其他RD类别(p≤0.001),RD 0.1-1.0cm优于RD>1cm(p=0.01)。
- 标准化后RD0从32.7%升至54.3%,RD>1cm从20.3%降至7.3%,中位总生存从36个月延长至40个月。
核心结论
- RD0患者总生存最长,RD 0.1-1.0cm较RD>1cm有生存优势。
- 数据支持即使无法达到RD0,也应将初次肿瘤细胞减灭术做到最低残留病灶。
- 实践改进可提高RD0率并改善总生存,且不增加并发症。
研究设计与样本
- 回顾性收集2003至2011年接受初次肿瘤细胞减灭术的FIGO(2009)IIIC期卵巢癌患者447例(平均年龄65.3岁)。
- 队列按时间段分为2003-2006年(n=202)与2007-2011年(n=245),比较细胞减灭标准化前后的结局。
- 残留病灶分为RD0、RD 0.1-0.5cm、RD 0.6-1.0cm和RD>1cm四类。
- 采用Kaplan-Meier法估计总生存和无进展生存。
主要发现
- 全队列RD分布:RD0占44.5%,RD 0.1-0.5cm占30.9%,RD 0.6-1.0cm占11.4%,RD>1cm占13.2%。
- 中位总生存分别为RD0 58个月、RD 0.1-0.5cm 35个月、RD 0.6-1.0cm 29个月、RD>1cm 22个月。
- RD0总生存显著优于其他所有RD类别(p≤0.001),RD 0.1-1.0cm优于RD>1cm(p=0.01)。
- 2003-2006年与2007-2011年比较:RD0从32.7%升至54.3%(p<0.001),RD>1cm从20.3%降至7.3%(p<0.001)。
- 手术复杂度从24.3%升至41.2%;30天Accordion 3-4级并发症发生率18.8% vs 20.8%(p=0.60),无显著差异;30天死亡率从4.5%降至1.2%(p=0.035);中位总生存从36个月延长至40个月。
临床怎么用
- 作者认为数据支持将初次肿瘤细胞减灭术做到最低残留病灶,即使无法达到RD0。
- 作者认为实践改进可提高RD0率并改善总生存,且不增加并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to determine survival associated with residual disease (RD) after primary debulking surgery (PDS) for advanced ovarian cancer (OC), and evaluate impact on complications and survival after practice changes to improve PDS. METHODS: Outcome variables were collected for patients undergoing PDS for FIGO (2009) stage IIIC OC from 2003 to 2011. The cohort was divided into time periods (2003-2006 vs. 2007-2011), before and after cytoreduction standardization. RD categories were: RD0, RD 0.1-0.5cm, RD 0.6-1.0cm, and RD>1cm. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. RESULTS: 447 patients (mean age, 65.3years) met inclusion criteria. RD for the entire cohort: RD0=44.5%; RD 0.1-0.5cm=30.9%; RD 0.6-1.0cm=11.4%; and RD>1cm=13.2%, with median OS of 58months, 35months, 29months, and 22months, respectively. OS was significantly better for RD0 vs. all other RD categories (p≤0.001), and for RD 0.1-1.0cm vs. RD>1cm (p=0.01). RD0 improved from 32.7% to 54.3% (p<0.001), and RD>1cm decreased from 20.3% to 7.3% (p<0.001) when comparing the 2003-2006 (n=202) vs. 2007-2011 (n=245) cohorts. Surgical complexity increased in the latter time period (24.3% vs. 41.2%). 30-day Accordion grade 3-4 morbidity remained consistent (18.8% vs. 20.8%, p=0.60), 30-day mortality decreased (4.5% to 1.2%, p=0.035), and median OS improved from 36 to 40months after cytoreduction standardization. CONCLUSION: Patients with RD0 had longest OS, with survival advantage for RD1 when compared to RD>1cm. These data support PDS to lowest RD even when RD0 cannot be obtained. Practice improvement efforts can increase RD0 rates, improving OS without compromising morbidity.
引用
- Wallace S, Kumar A, Mc Gree M, et al. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol. 2017. PMID: 28159407. doi:10.1016/j.ygyno.2017.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。